Mina S. Sedrak

• Associate Professor with Tenure, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA (2023–Present)
• Director, Cancer & Aging Program, UCLA Jonsson Comprehensive Cancer Center (2023–Present)
• Director, Cancer Control & Survivorship Research Program, UCLA Jonsson Comprehensive Cancer Center (2025–Present)
• Breast Medical Oncologist, UCLA Health – Encino & Parkside Cancer Care (2023–Present)

LECTURES AND PRESENTATIONS

1. Innovative Strategies for Coaching Residents
   Association of Program Directors in Internal Medicine, Fall Meeting, Atlanta, GA — 04/01/2015
2. Technology-based Approaches to Improve Quality Cancer Care
   City of Hope, Duarte, CA — 01/15/2016
3. Structuring and Implementing a High Value Care–Quality Improvement Curriculum in Your Training Program
   American College of Physicians, Philadelphia, PA — 03/01/2016
4. Cancer Communication in the Social Media Age
   Women’s Cancer Annual Retreat, City of Hope, Monrovia, CA — 10/21/2016
5. Using Social Media to Improve Cancer Clinical Trial Participation
   Iovine & Young Academy Innovators Forum, USC, Los Angeles, CA — 03/06/2017
6. Cancer Research in the New Communication Landscape
   Waisman Innovations Award Ceremony, City of Hope, Duarte, CA — 08/28/2017
7. Clinical Trials in Older Adults with Cancer
   Cancer Control and Population Sciences Retreat, City of Hope, Monrovia, CA — 01/29/2018
8. Integrating Social Media in Modern Oncology Practice and Research
   Grand Rounds, City of Hope, Duarte, CA — 03/13/2018
9. Identifying Barriers to Clinical Trial Participation among Older Adults with Breast Cancer and Their Caregivers
   Circle 1500 Foundation, Duarte, CA — 04/19/2018
10. Barriers to Clinical Trial Participation for Older Adults with Cancer
    Cancer in Older Adult Committee, Alliance Spring Meeting, Chicago, IL — 05/12/2018
11. Social Media & Cancer Care: Noisy Chatter or Meaningful Discourse?
    Phase One Foundation, Los Angeles, CA — 05/15/2018
12. Leveraging Social Media to Advance Cancer Research: Challenges and Opportunities
    American Society of Clinical Oncology Annual Meeting, Chicago, IL — 06/02/2018
13. Engaging the Aging: Enhancing Clinical Trial Participation for Older Adults with Cancer
    At the Crossroads of Social Media and Clinical Trials, NCI, Bethesda, MD — 06/07/2018
14. Enhancing Clinical Trial Participation for Older Adults with Cancer
    NCI Diversifying Accrual Research Interest Group, Bethesda, MD — 06/21/2018
15. Community and Academic Oncologists’ Perceptions of Barriers to Clinical Trial Enrollment of Older Adults with Cancer
    International Society of Geriatric Oncology, Amsterdam, Netherlands — 11/16/2018
16. Improving Access and Participation in Clinical Trials for Older Women with Breast Cancer
    Circle 1500, Palos Verde Peninsula, CA — 01/24/2019
17. Precision Medicine for Older Patients with Breast Cancer
    Women’s Cancer Annual Retreat, City of Hope, Monrovia, CA — 03/08/2019
18. Clinical Predictors of Chemotherapy Toxicity in Older Patients with Breast Cancer
    Cancer Control and Population Sciences Retreat, City of Hope, Monrovia, CA — 03/18/2019
19. Treatment Strategies in Octogenarians with Early Stage, High-Risk Breast Cancer
    Society of Surgical Oncology Annual Meeting, San Diego, CA — 03/28/2019
20. A Legacy of Hope: Celebrating Arti Hurria, MD
    Cancer in Older Adult Committee, Alliance Spring Meeting, Chicago, IL — 05/11/2019
21. Navigating the Job Search
    Fellows and Trainees Lounge, ASCO Annual Meeting, Chicago, IL — 06/02/2019
22. Improving the Care of Older Patients with Breast Cancer
    Supportive Care Retreat, City of Hope, Duarte, CA — 07/23/2019
23. Clinical Trials Designed for Older Adults with Cancer
    Medical Oncology Retreat, City of Hope, Duarte, CA — 01/31/2020
24. Randomized Controlled Pilot Study of Low-dose vs. Standard-dose Chemotherapy in Older Patients with Early-Stage Breast Cancer
    Cancer Control and Population Sciences Retreat, City of Hope, Duarte, CA — 02/28/2020
25. Breast Cancer in Older Adults: Clinical and Biological Implications for Therapy
    Advanced Biology Course, Beckman Graduate School, Duarte, CA — 02/29/2020
26. Breast Cancer in Older Women: Understanding Differences to Improve Outcomes
    City of Hope Community Network, Duarte, CA — 08/25/2020
27. Breast Cancer in Older Adults: Clinical and Biological Implications for Therapy
    Breast Surgical Oncology Fellowship, City of Hope, Duarte, CA — 09/23/2020
28. Improving the Evidence Base for Treatment Decision-Making for Older Adults with Cancer
    National Cancer Policy Forum, Virtual Symposium — 01/22/2021
29. Relative Dose Intensity in Older Adults with Cancer
    Cancer and Aging R33 Infrastructure Grant Conference, Virtual Symposium — 01/28/2021
30. Infrastructure to Support Accrual of Older Adults to Clinical Trials
    Engaging Older Adults in the NCI Clinical Trials Network, Virtual NCI Meeting — 04/26/2021
31. Cancer Care in an Aging Population: Charting the Path Forward
    K12 Scholar Meeting, Virtual — 05/05/2021
32. Older Adults in Cancer Trials
    Tideswell and American Geriatrics Society, Virtual Meeting — 05/11/2021
33. Making Cancer Trials Available to Older Adults
    American Society of Clinical Oncology Annual Meeting — 06/04/2021
34. Breast Cancer in Older Adults: Clinical and Biological Implications for Therapy
    National Institute of Health Sciences & Nutrition Salvador Zubirán, Mexico City — 06/09/2021
35. What I Wish I Knew Before Starting Fellowship
    Hematology Oncology Fellows, City of Hope, Duarte, CA — 07/12/2021
36. Clinical Trial Accrual of Older Adult Population
    NCORP Annual Meeting, Virtual — 08/25/2021
37. Senescent Cells in Cancer Therapy: Why and How to Remove Them
    UNC Geriatric Oncology Research Symposium, Chapel Hill, NC — 11/19/2021
38. Senescence and Functional Decline after Chemotherapy in Older Adults with Breast Cancer
    Duke Pepper Center, Durham, NC — 01/13/2022
39. Senescence and Functional Decline after Chemotherapy in Older Adults with Cancer
    UConn Center on Aging Grand Rounds, Storrs, CT — 05/10/2022
40. Leveraging Paradigms in Aging to Optimize Cancer Care
    Department of Medical Oncology, City of Hope, Duarte, CA — 01/12/2023
41. Lessons I’ve Learned as an Early-Stage Investigator
    Cancer Control & Population Sciences Annual Retreat, City of Hope, Duarte, CA — 03/03/2023
42. Translational Research at the Aging and Cancer Interface
    Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA — 03/10/2023
43. Translational Research at the Aging and Cancer Interface
    UCLA Jonsson Comprehensive Cancer Center Special Seminar, Los Angeles, CA — 03/14/2023
44. Lessons Learned from the Conduct of Clinical Trials
    NIA Roybal Centers for Translational Research Annual Meeting, Bethesda, MD — 03/14/2023
45. Translational Research at the Aging and Cancer Interface
    USC Norris Comprehensive Cancer Center Special Seminar, Los Angeles, CA — 03/20/2023
46. Optimizing the Health of Cancer Patients and Survivors by Targeting the Biology and Heterogeneity of Aging
    NCI Perspectives on Cancer & Aging, Bethesda, MD — 04/03/2023
47. Cancer and Accelerated Aging
    NIA Fourth Geroscience Summit, Bethesda, MD — 04/24/2023
48. Translating Discoveries from Aging Biology into New Therapies for Cancer Patients
    The Glenn Foundation for Medical Research Annual Workshop, Santa Barbara, CA — 05/31/2023
49. Finding Your Tribe with ASCO’s Communities of Practice
    ASCO Annual Meeting, Chicago, IL — 06/04/2023
50. Targeting Cancer Treatment-Induced Senescence Using Senolytics
    Second Annual Symposium on Healthy Aging, Georgetown University — 07/12/2023
51. Optimizing Health Outcomes of Cancer Patients and Survivors by Targeting the Biology and Heterogeneity of Aging
    Keynote Speaker, Geriatric Oncology Annual Symposium, UNC, Chapel Hill, NC — 12/01/2023
52. Sex and Age: Biological Variables in Breast Cancer
    Discussant, San Antonio Breast Cancer Symposium, San Antonio, TX — 12/07/2023
53. Targeting the Biology of Aging to Improve the Health of Cancer Patients and Survivors
    Department of Surgery Research Forum, City of Hope, Los Angeles, CA — 12/14/2023
54. Targeting the Biology of Aging to Improve the Health of Cancer Survivors
    OncLive State of the Science Summit: Breast Cancer, Los Angeles, CA — 01/09/2024
55. Living Well During Cancer and Beyond: The Science of Cancer and Aging
    Keynote Speaker, Women’s Cancer Survivors Conference, UCLA, CA — 03/03/2024
56. Optimizing Health of Cancer Survivors by Targeting the Biology of Aging
    Invited Lecturer, Health Psychology Seminar, UCLA, Los Angeles, CA — 03/06/2024
57. Targeting the Biology of Aging to Improve Health Outcomes of Cancer Survivors
    Cancer Outcomes Seminar, University of Alabama at Birmingham — 04/10/2024
58. Targeting Senescence to Improve Health Outcomes of Cancer Survivors
    Cancer Control & Prevention Monthly Seminar, UCLA, Los Angeles, CA — 04/24/2024
59. Targeting the Biology of Aging to Improve the Health Outcomes of Cancer Survivors
    Grand Rounds, Medical College of Wisconsin, Milwaukee, WI — 04/26/2024
60. Translational Research at the Interface of Cancer and Aging
    Cancer Grand Rounds, University of Michigan, Ann Arbor, MI — 04/29/2024
61. Translational Research at the Interface of Cancer and Aging
    Cancer in Older Adult Committee, Alliance Spring Meeting, Chicago, IL — 05/17/2024
62. Lessons I’ve Learned as an Early-Stage Investigator
    Hematology/Oncology Fellowship Program, UCLA, Los Angeles, CA — 06/11/2024
63. Five Things I Learned from Grant Writing
    International Society of Geriatric Oncology, Montreal, Canada — 10/17/2024
64. What Is Host Resilience, and Does It Matter?
    Keynote Speaker, 4th International Conference on Toxicities of Transplantation & Cellular Therapies (ASTCT), Philadelphia, PA — 11/15/2024
65. Breast Cancer and Aging Research
    Award Recipient Speech, Susan G. Komen Breast Cancer Research Award Ceremony, San Antonio, TX — 12/11/2024
66. Breast Cancer in the Older Adult
    Chair, Educational Session, San Antonio Breast Cancer Symposium, TX — 12/12/2024
67. Stress, Senescence, and Cellular Aging in Cancer
    Chair, Major Symposium, AACR Annual Meeting, Chicago, IL — 04/30/2025
68. Enhancing Clinical Trials for Older Adults with Cancer: Integrating Geriatric Principles into Design and Implementation
    Invited Speaker, SWOG Special Symposium, San Francisco, CA — 05/01/2025
69. Quality Care / Health Services Research Rapid Oral Session
    Chair, ASCO Annual Meeting, Chicago, IL — 06/01/2025
70. Keys to Success for the Early Career Oncologist
    Panelist, ASCO Trainee & Early Career Lounge, Chicago, IL — 06/02/2025
71. Improving Access & Evidence: Ensuring Older Adults Benefit from Cancer Clinical Research
    Invited Speaker, ASCO Headquarters, Alexandria, VA — 06/25/2025
72. Targeting Aging Biology to Optimize the Long-Term Health of Cancer Survivors
    Early Career Scientist Spotlight Research Seminar Series, NCI — 07/10/2025
73. What Every Oncologist Should Know About Aging and Cancer — And Why It Matters Now
    Grand Rounds, UMass Chan–Baystate Hematology Oncology Division, Springfield, MA — 07/25/2025
74. Accelerated Aging in Patients Undergoing Systemic Therapy for Breast Cancer
    Invited Speaker, DAVA Breast Cancer Summit, Kona, Hawaii — 08/23/2025
75. Toxicity Risk Prediction and Dose Intensity in Older Adults with Early Breast Cancer: Results from the HOPE Study
    Invited Speaker, DAVA Breast Cancer Summit, Kona, Hawaii — 08/23/2025
76. Hands-on Geriatric Assessment: Practical Tools for Age-Inclusive Cancer Research
    Invited Speaker, SWOG Special Symposium, Chicago, IL — 09/19/2025

PUBLICATIONS / BIBLIOGRAPHY

1. A. Research Papers – Peer-Reviewed
   Rubin DT, Huo D, Kinnucan JA, Sedrak MS, et al. Inflammation is an independent risk factor for colonic neoplasia in ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013;11(12):1601–1608.e1-4.
2. Sedrak MS, Cohen RB, Merchant RM, Schapira MM. Cancer communication in the social media age. JAMA Oncol. 2016;2(6):822–823.
3. Attai DJ, Sedrak MS, Katz MS, et al. Social media in cancer care: highlights, challenges & opportunities. Future Oncol. 2016;12(13):1549–1552.
4. Sedrak MS, Patel MS, Ziemba JB, et al. Residents’ self-report on ordering unnecessary inpatient laboratory tests. J Hosp Med. 2016;11(12):869–872.
5. Sedrak MS, Dizon DS, Anderson PF, et al. The emerging role of professional social media use in oncology. Future Oncol. 2017;13(15):1281–1285.
6. Sedrak MS, Myers JS, Small DS, et al. Price transparency intervention and inpatient laboratory test ordering: PRICE randomized clinical trial. JAMA Intern Med. 2017;177(7):939–945.
7. Attai DJ, Anderson PF, Fisch MJ, et al. Risks and benefits of Twitter use by oncologists. Semin Hematol.2017;54(4):198–204.
8. DeKosky AS, Sedrak MS, Goren E, et al. Frameworks for coaching residents in time management and efficiency. J Grad Med Educ. 2018;10(3):325–330.
9. Battisti NML, De Glas N, Sedrak MS, et al. CDK4/6 inhibitors in older ER+/HER2– breast cancer patients. Ther Adv Med Oncol. 2018;10:1758835918809610.
10. Dizon DS, Sedrak MS, Lewis MA, et al. Digital tools to improve cooperative group clinical trials. JCO Clin Cancer Inform. 2018;2:1–8.
11. Shinde A, Akhavan D, Sedrak MS, et al. Whole-brain radiation vs radiosurgery for brain metastases. CNS Oncol.2019;8(1):CNS27.
12. Sedrak MS, Salgia MM, Bergerot PG, et al. Public communication about kidney cancer on Twitter. JCO Clin Cancer Inform. 2019;3:1–6.
13. Dao D, Zemla T, Jatoi A, Sedrak MS, et al. Older-patient–specific cancer trials: pooled analysis (A151715). Oncologist. 2019;24(6):e284–e291.
14. Chen BT, Jin T, Patel SK, et al. Brain activity changes with chemotherapy in older women with breast cancer. Breast Cancer Res Treat. 2019;176(1):181–189.
15. Alliance Cancer in Older Adult Committee; Sedrak MS, et al. Tribute to Arti Hurria. J Geriatr Oncol.2020;11(2):179–183.
16. Chien L, Roberts E, Soto-Perez-de-Celis E, Sedrak MS, et al. Telehealth in geriatric oncology. J Geriatr Oncol.2020;11(2):197–199.
17. Sedrak MS, Li D, Walter LC, et al. CARG cores for geriatric oncology research infrastructure. J Geriatr Oncol.2020;11(2):355–358.
18. Sedrak MS, Mohile SG, Sun V, et al. Barriers to clinical trial enrollment of older adults: oncologist perspectives. J Geriatr Oncol. 2020;11(2):327–334.
19. DuMontier C, Sedrak MS, Soo WK, et al. Integrating geriatric assessment into oncology. J Geriatr Oncol.2020;11(2):203–211.
20. Shinde A, Vazquez J, Novak J, Sedrak MS, et al. Geriatric assessment in radiation oncology. J Geriatr Oncol.2020;11(2):194–196.
21. Sedrak MS, Sun V, Liu J, et al. Physician perceptions of social media for clinical trial recruitment. JAMA Netw Open. 2019;2(9):e1911528.
22. Slavin TP, Sun CL, Sedrak MS, et al. Hereditary cancer predisposition and clonal hematopoiesis in older breast cancer survivors. J Geriatr Oncol. 2020;11(2):316–319.
23. Chen BT, Ye N, Wong CW, et al. Chemotherapy-induced aging white matter changes. J Geriatr Oncol.2020;11(2):290–296.
24. Ludmir EB, Subbiah IM, Sedrak MS, et al. Declining upper age restrictions in cancer clinical trials. J Geriatr Oncol. 2020;11(3):451–454.
25. Li R, Vazquez J, Sedrak MS, et al. Treatment of non-metastatic pancreatic cancer in patients ≥80 years. J Geriatr Oncol. 2020;11(4):652–659.
26. Sammons S, Sedrak MS, Kimmick GG. Treating HR+/HER2– breast cancer in older adults – Part I. Drugs Aging.2020;37(5):331–348.
27. Hill A, Gutierrez E, Sedrak MS, et al. HR+/HER2– breast cancer in older adults – Part II. Drugs Aging.2020;37(5):349–358.
28. Magnuson A, Li D, Sedrak MS, et al. Mentoring lessons from Arti Hurria. J Geriatr Oncol. 2020;11(2):335–337.
29. Wong AR, Sun V, Liu J, Sedrak MS, et al. Barriers to therapeutic trial participation. JCO Oncol Pract.2020;16(9):e849–e858.
30. Sedrak MS, Soto-Perez-de-Celis E, Nelson RA, et al. Online health information seeking in older women with chronic illness. J Med Internet Res. 2020;22(4):e15906.
31. Liu J, Gutierrez E, Sedrak MS, et al. Increasing older adult participation in research. J Clin Med. 2020;9(5):1571.
32. Presant CA, Salgia R, Sedrak MS, et al. Lung cancer screening and prevention implementation. J Clin Med.2020;9(6):1820.
33. Mortimer JE, Kruper L, Sedrak MS, et al. HER2-directed therapy patterns in metastatic breast cancer. J Clin Med. 2020;9(6):1984.
34. Novak J, Cui Y, Sedrak MS, et al. Growth of the #RadOnc Twitter network. Pract Radiat Oncol.2021;11(3):e263–e266.
35. Sedrak MS, Freedman RA, Muss HB, et al. Older adult participation in clinical trials: systematic review. CA Cancer J Clin. 2021;71(1):78–92.
36. Cushman TR, Jones B, Sedrak MS, et al. Time-to-treatment for NSCLC patients in the U.S. Clin Lung Cancer.2021;22(1):e84–e97.
37. Yuan Y, Lee JS, Sedrak MS, et al. Pembrolizumab + enobosarm for AR–positive TNBC. Oncologist.2021;26(2):99–e217.
38. Chávarri-Guerra Y, Hendricks CB, Sedrak MS, et al. Pathogenic variants in older women with TNBC. J Geriatr Oncol. 2021;12(5):749–751.
39. Sedrak MS, Sun CL, Hershman DL, et al. Social media for clinical trial recruitment. JAMA Netw Open.2021;4(3):e215118.
40. Sedrak MS, Magnuson A, Gross CP, et al.** Risk tool for predicting severe toxicity in older adults with early-stage breast cancer. J Clin Oncol. 2021;39(6):608–618. (*Co-first authors)
41. Freedman RA, Minami CA, Winer EP, et al. Individualizing surveillance mammography for older breast cancer survivors: SIOG consensus statement. JAMA Oncol. 2021;7(4):609–615. doi:10.1001/jamaoncol.2020.7582. PMCID: PMC8944384.
42. Yuan Y, Lee JS, Yost SE, et al. Phase II study of neratinib in older adults with HER2-amplified or HER2/3-mutated metastatic breast cancer. J Geriatr Oncol. 2021;12(5):752–758. doi:10.1016/j.jgo.2021.02.020. PMCID: PMC8580161.
43. Guerard E, Dodge AB, Le-Rademacher JG, et al. Electronic geriatric assessment feasibility in a multi-institutional study (Alliance A171603). JCO Clin Cancer Inform. 2021;5:435–441. doi:10.1200/CCI.20.00163. PMCID: PMC8240783.
44. Loh KP, Lam V, Webber K, et al. Functional changes during systemic cancer therapy in older adults: systematic review. J Natl Compr Canc Netw. 2021;19(9):1055–1062. doi:10.6004/jnccn.2020.7684. PMCID: PMC8517039.
45. Chen BT, Chen Z, Patel SK, et al. Chemotherapy effects on default mode network connectivity in older women with breast cancer. Brain Imaging Behav. 2022;16(1):43–53. doi:10.1007/s11682-021-00475-y. PMCID: PMC8606014.
46. Freedman RA, Sedrak MS, Bellon JR, et al. Managing older adults with breast cancer amid COVID-19. J Natl Cancer Inst. 2021;113(4):355–359. doi:10.1093/jnci/djaa079. PMCID: PMC7313961.
47. Sedrak MS, Gilmore NJ, Carroll JE, et al. Measuring biologic resilience in older cancer survivors. J Clin Oncol.2021;39(19):2079–2089. doi:10.1200/JCO.21.00245. PMCID: PMC8260901.
48. Soto-Perez-de-Celis E, Vazquez J, Kim H, et al. Spanish-language geriatric assessment for older adults with breast cancer. Cancers (Basel). 2021;13(11):2685. doi:10.3390/cancers13112685. PMCID: PMC8198244.
49. Miyano M, Sayaman RW, Shalabi SF, et al. Breast-specific molecular clocks identifying susceptibility to cancer initiation. Cancer Prev Res. 2021;14(8):779–794. doi:10.1158/1940-6207.CAPR-20-0635. PMCID: PMC8338914.
50. Yuan Y, Lee JS, Yost SE, et al. Palbociclib, pembrolizumab, and letrozole for HR+ metastatic breast cancer: Phase I/II trial. Eur J Cancer. 2021;154:11–20. doi:10.1016/j.ejca.2021.05.035. PMCID: PMC8691850.
51. Dotan E, Walter LC, Browner IS, et al. NCCN Guidelines Insights: Older Adult Oncology, Version 1.2021. J Natl Compr Canc Netw. 2021;19(9):1006–1019. doi:10.6004/jnccn.2021.0043.
52. Li D, Charles K, Hughes S, et al. GAIN trial: geriatric assessment–driven intervention for older adults on chemotherapy. JAMA Oncol. 2021;7(11):e214158. doi:10.1001/jamaoncol.2021.4158. PMCID: PMC8485211.
53. Chow R, Lage DE, Williams GR, et al. Representation of older adults in practice-changing oncology trials. J Natl Compr Canc Netw. 2022;20(1):37–44. doi:10.6004/jnccn.2021.7055. PMCID: PMC9271368.
54. Li D, Imbesi GJ, Yen L, et al. Self-assessment tool NET VITALS feasibility among neuroendocrine tumor patients. Pancreas. 2022;51(4):319–324. doi:10.1097/MPA.0000000000002034.
55. Ji J, Sun CL, Cohen HJ, et al. Inflammation and clinical decline after chemotherapy in older adults with breast cancer. J Clin Oncol. 2023;41(2):307–315. doi:10.1200/JCO.22.01217. PMCID: PMC9839275.
56. Freedman RA, Li T, Sedrak MS, et al. ADVANCE trial: low-toxicity chemotherapy for older adults. J Geriatr Oncol.2023;14(1):101377. doi:10.1016/j.jgo.2022.09.006. PMCID: PMC10080267.
57. Sedrak MS, Ji J, Tiwari A, et al. Clinical trial enrollment differences between older vs younger adults. JAMA Netw Open. 2022;5(10):e2235714. doi:10.1001/jamanetworkopen.2022.35714. PMCID: PMC9552900.
58. Chen BT, Chen Z, Deng F, et al. Signal variability and cognitive function in older long-term breast cancer survivors. Brain Sci. 2022;12(10):1283. doi:10.3390/brainsci12101283. PMCID: PMC9599386.
59. Daniel E, Deng F, Patel SK, et al. Cortical thinning after chemotherapy in older breast cancer survivors. Brain Imaging Behav. 2023;17(1):66–76. doi:10.1007/s11682-022-00743-5. PMCID: PMC10156471.
60. Sedrak MS, Sun CL, Ji J, et al. Low-intensity adjuvant chemotherapy in older women with breast cancer: HOPE trial. J Clin Oncol. 2023;41(2):316–326. doi:10.1200/JCO.22.01440. PMCID: PMC9839299.
61. Sedrak MS, Cohen HJ. The aging–cancer cycle: mechanisms & interventions. J Gerontol A Biol Sci Med Sci.2023;78(7):1234–1238. doi:10.1093/gerona/glac247. PMCID: PMC10329223.
62. Sedrak MS, Kimmick G, Williams G, et al.** Infrastructure to support accrual of older adults to NCI trials. J Natl Cancer Inst Monogr. 2022;60:151–158. doi:10.1093/jncimonographs/lgac025. PMCID: PMC9753220.
63. Le-Rademacher J, Mohile S, Unger J, et al. Trial design to increase older adult accrual to NCI trials. J Natl Cancer Inst Monogr. 2022;60:135–141. doi:10.1093/jncimonographs/lgac023. PMCID: PMC9949574.
64. Yilmaz S, Koita F, Zittel J, et al. Self-perceived age and chemotherapy decisions. J Geriatr Oncol. 2023;14(2):101429. doi:10.1016/j.jgo.2023.101429. PMCID: PMC9974899.
65. Ji J, Sun C, Cohen HJ, et al. Toxicity risk score and clinical decline after adjuvant chemotherapy. J Natl Cancer Inst.2023;115(5):578–585. doi:10.1093/jnci/djad029. PMCID: PMC10165485.
66. Mahin D, Lavasani SM, Cristobal L, et al. Hyperglycemia with glucocorticoids in early-stage breast cancer. J Clin Med. 2023;12(5):1906. doi:10.3390/jcm12051906. PMCID: PMC10004215.
67. Ge X, Behrendt CE, Yost SE, et al. Predicting hyperglycemia in patients receiving alpelisib. Oncologist.2023;28(7):e488–e492. doi:10.1093/oncolo/oyad024. PMCID: PMC10322119.
68. Mayerhofer C, Sedrak MS, Hopkins JO, et al. Clonal hematopoiesis in older patients receiving chemotherapy. J Natl Cancer Inst. 2023;115(8):981–988. doi:10.1093/jnci/djad065. PMCID: PMC10407695.
69. Mokhnatkin JV, Bae M, Dale W, et al. Barriers to clinical trial enrollment for older adults and caregivers. JCO Oncol Pract. 2023;19(7):484–492. doi:10.1200/OP.22.00843. PMCID: PMC10337716.
70. Daniel E, Deng F, Patel SK, et al. Altered gyrification after chemotherapy in older survivors. Brain Behav.2024;14(8):e3634. doi:10.1002/brb3.3634. PMCID: PMC10120747.
71. Lee K, Shamunee J, Lindenfeld L, et al. Telehealth exercise in frail HCT survivors. BMC Cancer. 2023;23:390. doi:10.1186/s12885-023-10884-5. PMCID: PMC10150529.
72. Nelson R, Soto-Perez-de-Celis E, Chlebowski RT, et al. Predicting mortality in women with and without breast cancer using the Schonberg Index. J Natl Compr Canc Netw. 2023;21(6):636–644.e13. doi:10.6004/jnccn.2023.7015.
73. Rainone M, Behrendt CE, Kasparian S, et al. HER2-targeted ADCs: ancestry and thrombocytopenia. Breast Cancer.2023;30(5):796–801. doi:10.1007/s12282-023-01473-2. PMCID: PMC10404202.
74. Ji J, Bae M, Sun CL, et al. Falls and toxicity-related hospitalization in older women receiving adjuvant chemotherapy (HOPE trial). Cancer. 2024;130(6):936–946. doi:10.1002/cncr.35105. PMCID: PMC10922500.
75. Daniel E, Deng F, Patel SK, et al. White matter microstructural changes post-chemotherapy. Cancer Med.2024;13(1):e6881. doi:10.1002/cam4.6881. PMCID: PMC10807556.
76. Lustberg M, Fan-Havard P, Wong L, et al. Nanoemulsion curcumin for AI-induced arthropathy: randomized pilot trial. Breast Cancer Res Treat. 2024;205(1):61–73. doi:10.1007/s10549-023-07223-4. PMCID: PMC11062803.
77. Daniel E, Deng F, Patel SK, et al. Hippocampal volume and shape changes post-chemotherapy. Front Aging Neurosci.2024;16:1347721. doi:10.3389/fnagi.2024.1347721. PMCID: PMC10957749.
78. Soto-Perez-de-Celis E, Dale W, Katheria V, et al. Outcome prioritization among older adults starting chemotherapy. Cancer. 2024;130(17):3000–3010. doi:10.1002/cncr.35333. PMCID: PMC11863993.
79. Sedrak MS, Sun CL, Bae M, et al. Functional decline in older breast cancer survivors with/without chemotherapy: HOPE study. J Cancer Surviv. 2024;18(4):1131–1143. doi:10.1007/s11764-024-01594-3. PMCID: PMC11324395.
80. Sedrak MS, Lee MK, Ji J, et al. Palbociclib in adults ≥70 years with advanced breast cancer: Alliance A171601. J Geriatr Oncol. 2024;15(6):101813. doi:10.1016/j.jgo.2024.101813. PMCID: PMC11259237.
81. Hanlon E, Diaz ANR, Sedrak MS, et al. Frailty and cancer therapy–associated cardiotoxicity. J Geriatr Oncol.2024;15(8):101835. doi:10.1016/j.jgo.2024.101835. PMCID: PMC11560719.
82. Wong MH, Jones VC, Yu W, et al. UGT1A1*28 polymorphism and sacituzumab govitecan toxicity and progression. Cancer Med. 2024;13(16):e70096. doi:10.1002/cam4.70096. PMCID: PMC11331244.
83. Mandelblatt JS, Antoni MH, Bethea TN, et al. Gerotherapeutics to reduce cancer disparities. J Natl Cancer Inst.2025;117(3):406–422. doi:10.1093/jnci/djae211. PMCID: PMC11884862.
84. Cabrera Chien L, Sun CL, Kim H, et al. GAIN-HOSP: geriatric assessment interventions for hospitalized older adults. J Geriatr Oncol. 2025;16(1):102063. doi:10.1016/j.jgo.2024.102063. PMCID: PMC11824465.
85. Bardia A, Rugo HS, Sedrak MS, et al. Q-TWiST benefit-risk analysis of sacituzumab govitecan in metastatic TNBC. JCO Oncol Pract. 2025;OP2400806. doi:10.1200/OP-24-00806.

Office: David Geffen School of Medicine at UCLA, Center for Cancer Prevention & Control Research, 650 Charles Young Drive South, A2-125 CHS, Los Angeles, CA 90095
Email: [email protected]